.jpg)
.png)
Last Updated: Monday, 03-Aug-2020 16:00:00 EDT
The National Lipid Association is excited to announce a month-long extravaganza of virtual education, LipidPALOOZA, launching this September to celebrate National Cholesterol Education Month. There will be a variety of activities spread throughout the entire month and best of all, they will be offered at no charge.
Each Friday in September, LipidPALOOZA will feature a half-day of sensational content comprised of:
Last Updated: Friday, 17-Jul-2020 20:15:00 EDT
View the July 2020 SELA E-Newsletter by clicking here.
Testosterone is a predominantly male hormone responsible for virilization of the external male genitalia during embryonic development, promotion of somatic growth, and secondary sexual characteristics in puberty, normal sexual function and libido in both males and females, and promotion of bone formation, bone health and maintenance of bone and muscle mass in adults.(1,2) It circulates in females at approximately 13-14% of the level observed in males.(3) Testosterone levels in females d
Article By:
CHIMA NWIZU, MD, FAAFP, FNLA
Physician
Family Physicians of Greeley
Greeley, CO
Diplomate, American Board of Clinical Lipidology
Last Updated: Thursday, 02-Jul-2020 18:00:00 EDT
Join us Virtually in September for National Cholesterol Education Month
As we’ve monitored the trajectory of COVID-19 cases and local restrictions in the conference’s host city of Washington DC, we have decided to cancel the live Fall Clinical Lipid Update and associated pre-conference courses, scheduled for September 11-13, 2020.
Introduction
Article By:
LUKE HAMILTON, MS
Department of Pediatric Endocrinology and Diabetes
Cook Children’s Medical Center
Fort Worth, TX
DON P. WILSON, MD, FNLA
Department of Pediatric Endocrinology and Diabetes
Cook Children’s Medical Center
Fort Worth, TX
Diplomate, American Board of Clinical Lipidology
CATHERINE J. McNEAL, MD, PhD, FNLA
Department of Internal Medicine
Division of Cardiology
Baylor Scott and White Health
Temple, TX
Diplomate, American Board of Clinical Lipidology
Imagine the following scenario:
Article By:
NICOLE CIFFONE, MSN, ANP-C, AACC, CLS, FNLA
Nurse Practitioner
Arizona Center for Advanced Lipidology
Tucson, AZ
SUSAN HALLI-DEMETER, DNP, FNP-BC, CLS, FNLA
Nurse Practitioner
Mayo Clinic
Scottsdale, AZ
HMG-CoA reductase inhibitors (statins) were FDA-approved in 1987 and their introduction has revolutionized lipid and cardiovascular (CV) management for the past three decades.(1,2,3,4) Despite this, statins may be the most maligned pharmaceutical agents ever introduced. There are multiple potential causes for statin non-adherence and discontinuation. (5) Real and perceived side effects are cited as a critical contributor to this phenomenon.
Article By:
ROBERT E. LENDING, MD
Arizona Community Physicians
Cypress Concierge Medicine
Tucson, AZ
Diplomate, American Board of Clinical Lipidology
High density lipoprotein (HDL) has long been known as a negative risk factor for the development of atherosclerosis and cardiovascular disease. The traditional explanation of HDL’s atheroprotective effect is termed reverse cholesterol transport. In this process, HDL removes cholesterol from the periphery and delivers it to the liver to be excreted into the bile. However there are many other proposed protective mechanisms of HDL in addition to reverse cholesterol transport.
Article By:
NEIL SHETH, MD, FNLA
Senior Research Physician
Synexus Clinical Research
Glendale, AZ
Diplomate, American Board of Clinical Lipidology
Hypertriglyceridemia has become a point of great interest lately in the search for better management of residual risk in patients with established ASCVD. The Reduction of Cardiovascular Events with Icosapent Ethyl Intervention Trial (REDUCE-IT) as authored by Bhatt, DL et al, shows strong evidence that icosapent ethyl, in addition to statin, significantly reduced ASCVD risk in patients with hypertriglyceridemia.
Article By:
EDUARDO CABALLERO, MD
Mercedes, TX
Diplomate, American Board of Clinical Lipidology
JOSEPH L. LILLO, DO, CPI, FAPCR, FNLA
President, Southwest Lipid Association (2019-2020)
Associate Professor, Family Medicine
Midwestern University
Glendale, AZ
Private Practice
Scottsdale, AZ
Diplomate, American Board of Clinical Lipidology
T.S. is a 58-year-old male of South Asian origin who sought attention for complex dyslipidemia. He had migrated to the US in 1988. He has a strong family history positive for multiple members having coronary artery disease (CAD), percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), diabetes (DM) and one sibling with sudden cardiac death from a myocardial infarction (MI). He has been healthy all his life with no history of hypertension (HTN), smoking or DM.
Article By:
KRISHNASWAMI VIJAYARAGHAVAN, MD, FACC, FNLA
Medical Director, CHF
Abrazo Health Network
Clinical Professor of Medicine
University of Arizona
Phoenix, AZ
Diplomate, American Board of Clinical Lipidology
DINESH KALRA, MD, FACC, FSCCT, FSCMR
Associate Professor of Medicine
Rush Medical College
Director, Advanced Cardiac Imaging
Director, Lipid Clinic and Infiltrative Cardiomyopathy Program
Division of Cardiology, Rush Health System
Chicago, IL